FDA prioritizes Hope’s stem cell treatment with RMAT designation
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Hope Biosciences‘ adipose-derived mesenchymal stem cells (HB-adMSCs) to treat relapsing-remitting multiple sclerosis (RRMS). RMAT status is given to therapies with compelling proof that they may substantially improve patient outcomes compared with existing…